PIN80 CEFTAZIDIME-AVIBACTAM FOR THE TREATMENT OF CARBAPENEM-RESISTANT PATHOGENS ASSOCIATED WITH HEALTHCARE-ASSOSIATED INFECTIONS: A BUDGET IMPACT ANALYSIS IN ARGENTINA

Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam

a time-series analysis of the demand for life insurance in iran

با توجه به تجزیه و تحلیل داده ها ما دریافتیم که سطح درامد و تعداد نمایندگیها باتقاضای بیمه عمر رابطه مستقیم دارند و نرخ بهره و بار تکفل با تقاضای بیمه عمر رابطه عکس دارند

Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: "We're Gonna Need a Bigger Boat".

Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: “We’re Gonna Need a Bigger Boat” Brad Spellberg and Robert A. Bonomo Los Angeles County-University of Southern California Medical Center, and Division of Infectious Diseases, University of Southern California Keck School of Medicine, Los Angeles; and Departments of Medicine, Pharmacology, and Molecular Biology and Microbiology, ...

Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections

Carbapenem-resistant Enterobacteriaceae (CRE) infections are prevalent worldwide; they have few effective treatments and this jeopardizes public health. Clinicians often use tigecycline to combat CRE, but its clinical efficacy remains controversial. Therefore, to compare the efficacy and safety of tigecycline in treating CRE infections compared with that of other antimicrobial agents, and to ev...

Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections

This article provides a comprehensive review of currently available treatment options for infections due to carbapenem-resistant Enterobacteriaceae (CRE). Antimicrobial resistance in Gram-negative bacteria is an emerging and serious global public health threat. Carbapenems have been used as the "last-line" treatment for infections caused by resistant Enterobacteriaceae, including those producin...